New Hepatitis B Treatment vs Standard Drug
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests a new oral medication (ALG-000184) compared to an existing drug (tenofovir) for people with chronic hepatitis B who have not been treated recently. It aims to see if the new drug is better at lowering the virus and improving liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and have a body mass index (BMI) between 18 and 35.
- You have chronic hepatitis B and have either never been treated for it, or haven't taken any HBV medications in the last 6 months.
- Your blood test shows a high level of hepatitis B virus (HBV DNA at least 20,000 IU/mL).
- You do not have cirrhosis, advanced liver scarring, or any other liver infections like hepatitis C or HIV.
- You have not had liver cancer or any signs of liver damage from other causes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Hear when a new Chronic Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.